A puzzling case of seizures and visual hallucinations during clomipramine treatment with a high dose but causing a low serum concentration

Acta Psychiatrica Scandinavica

Volumn 99, Issue 5, 1999, Pages 388-390

  Terao, T ^a   Ohmori, O ^a   Shinkai, T ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Clomipramine; Cytochrome P450; Hallucinations; Seizures

Indexed keywords

CLOMIPRAMINE; CYTOCHROME P450 ISOENZYME; FLUNITRAZEPAM; LEVOMEPROMAZINE; LITHIUM CARBONATE; NORCLOMIPRAMINE;

ADULT; ALLELE; ARTICLE; CASE REPORT; DEPRESSION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; SEIZURE; SMOKING; VISUAL HALLUCINATION;

EID: 0032891568     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1999.tb07246.x     Document Type: Article

References (19)

1. 1. Edwards JG, Long SK, Sedgwick EM, Wheal HV. Antidepressants and convulsive seizures: clinical, electro-encephalograpic and pharmacological aspects. Clin Neuropharmacol 1986;9:329-360.
2. 2. Spigset O, Hedenmalm K, Dahl M-L, Wiholm B-E, Dahlovist R. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997;96:379-384.
3. 3. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquinine by allele-specific PCR amplification. Lancet 1990;336:529-532.
4. 4. Wang S-L, Huang J-D, Lai M-D, Lui B-H, Lai M-L. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-418.
5. 5. Lee EJD, Jeyaspeuan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol 1994;37:605-607.
6. 6. Tsuneoka Y, Matsuo Y, Ichikawa Y, Watanabe Y. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease. Metabolism 1998;47:94-96.
7. 7. Kubota T, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Phamacol Ther 1996;60:661-666.
8. 8. Mellstrom B, Bertilsson L, Traskman L et al. Intraindividual similarity in the metabolism of amitriptyline and clomipramine in depressed patients. Pharmacology 1979;19:282-287.
9. 9. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Phamacol 1994;46:452-459.
10. 10. Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995;58:264-268.
11. 11. Tseng CY, Wang SL, Lai MD, Lai ML, Huang JD. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1996;60:177-182.
12. 12. Yokota H, Tamura S, Furuya H et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993;3:256-263.
13. m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996;59:647-653.
14. 14. Feng HJ, Huang SL, Wang W, Zhou HH. The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 1998;45:27-29.
15. 15. Nielsen KK, Brøsen K, Hansen J, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphism. Clin Pharmacol Ther 1994;55:518-527.
16. 16. Bock KW, Schrenk D, Foster A et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine and paracetamol as probes. Pharmacogenetics 1994;4:209-218.
17. 17. Balant-Gorgia AE, Balant LP, Genei C et al. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986;31:449-455.
18. 18. Nielsen KK, Funois JP, Beaune P et al. The biotransformation of clomipramine in vitro; identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996;277:1659-1664.
19. 450 system: focus on venlafaxine, nefazodone and mirtazapine. Depression Anxiety 1998;7 (Suppl. 1):24-32.